Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.
Official title: A Phase II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2025-03-28
Completion Date
2028-12
Last Updated
2025-04-22
Healthy Volunteers
No
Conditions
Interventions
SHR-A2102
SHR-A2102 for injection.
Bevacizumab Injection
Bevacizumab injection.
Adebelimab Injection
Adebelimab injection.
Ametinib Mesylate Tablets
Ametinib mesylate tablets.
Osimertinib Mesylate Tablets
Osimertinib mesylate tablets.
Locations (1)
Shanxi Cancer hospital
Taiyuan, Shanxi, China